A randomized, double-blind clinical trial evaluates the efficacy of a novel Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe atopic dermatitis. A total of patients are randomized into one of four treatment arms: JAK inhibitor 15 mg, JAK inhibitor 30 mg, an active comparator (dupilumab), and placebo. The primary outcome is the absolute reduction in the Eczema Area and Severity Index (EASI) score from baseline to week 16. The data for this continuous variable are determined to be normally distributed, and Levene's test confirms homogeneity of variances across the groups.
Researchers perform a one-way analysis of variance (ANOVA) to evaluate whether there is a statistically significant difference in the mean EASI score reduction among the treatment groups. The -statistic is calculated by dividing the between-group mean square by the within-group mean square.
What is the within-group (denominator) degrees of freedom for this statistical test?
Answer: 424